According to the NCI website, sacituzumab govitecan is an antibody-drug conjugate containing the humanized monoclonal antibody, hRS7, against tumor-associated calcium signal transducer 2 (TACSTD2 or TROP2) and linked to the active metabolite of irinotecan, 7-ethyl-10-hydroxycamptothecin (SN-38), with potential antineoplastic activity. The antibody moiety of sacituzumab govitecan selectively binds to TROP2. After internalization and proteolytic cleavage, SN-38 selectively stabilizes topoisomerase I-DNA covalent complexes, resulting in DNA breaks that inhibit DNA replication and trigger apoptosis. TROP2, also known as epithelial glycoprotein-1 (EGP-1), is a transmembrane calcium signal transducer that is overexpressed by a variety of human epithelial carcinomas; this antigen is involved in the regulation of cell-cell adhesion and its expression is associated with increased cancer growth, aggressiveness and metastasis. Check for active clinical trials using this agent. (NCI Thesaurus)
Indikationen und Anwendungsmöglichkeiten gemäss COMPENDIUM®:
TRODELVY ist indiziert zur Behandlung von erwachsenen Patienten mit nicht resezierbarem lokal fortgeschrittenem oder metastasiertem triple-negativem Mammakarzinom (metastatic Triple-Negative Breast Cancer, mTNBC), die mindestens zwei Vortherapien erhalten haben, davon mindestens eine im metastasierten Stadium (siehe «Klinische Wirksamkeit»).
November 23, 2021: Trodelvy® (sacituzumab govitecan) Granted European Commission Marketing Authorization for Treatment of Metastatic Triple-Negative Breast Cancer in Second Line -- Marketing Authorization Based on Phase 3 ASCENT Study Showing Trodelvy Significantly Improved Overall Survival vs. Physician’s Choice of Chemotherapy in Metastatic Triple-Negative Breast Cancer
More Information in English:
Link to Drug Information Portal, a service of the U.S. National Library of Medicine, National Institutes of Health
Link to National Cancer Institute